Development and in vivo Evaluation of Hydroxy-α-Sanshool Intranasal Liposomes as a Potential Remedial Treatment for Alzheimer's Disease
Ruolan Li,Feng Lu,Xue Sun,Liying He,HuXinyue Duan,Wei Peng,ChunJie Wu
DOI: https://doi.org/10.2147/ijn.s339979
IF: 7.033
2022-01-11
International Journal of Nanomedicine
Abstract:Ruolan Li, &ast Feng Lu, &ast Xue Sun, Liying He, HuXinyue Duan, Wei Peng, ChunJie Wu State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Peng; ChunJie Wu Tel/Fax +86-28-61801001 Email ; Purpose: Hydroxy-α-sanshool (HAS) improves cognitive dysfunction, but its structural instability has limited its clinical application. The present study was conducted to investigate the optimal formulation of hydroxy-α-sanshool liposomes (HAS-LPs) and its effect on ameliorating learning and memory disorders in an Alzheimer's disease (AD) model. Methods: In this study, HAS was prepared as HAS-LP using a thin film dispersion method. After selecting the optimal preparation conditions, HAS-LP was characterized using transmission electron microscopy (TEM) and by measuring the zeta potential, particle size, and in vitro drug release. Next, evaluated the effect of HAS-LP on the rat nasal mucosa and then applied it to AD mice. By performing behaviour experiments, pathological test and related pharmacokinetic parameters, we explored its effect on attenuating learning and memory impairment in mice. Results: When the mass ratio of HAS:cholesterol:soybean lecithin was 1:4:16 and 15 mL of ultrapure water were added, the highest encapsulation efficiency and drug loading were obtained. HAS-LP had a particle size of 181.77 nm, a polydispersity index of 0.207 and a zeta potential of − 53.8 mV, and it remained stable at 25 °C for 1 week and 4 °C for 8 weeks. Moreover, HAS-LP exhibited slow drug release and was highly consistent with the Higuchi release model. HAS-LP was not significantly toxic to the nasal mucosa and effectively alleviated D-galactose-induced learning memory deficits and protected mouse hippocampal neuronal cells. HAS-LP was highly enriched in plasma and brain tissue after administration via the nasal route and obtained some ability to target the brain. Conclusion: HAS encapsulated in soybean lecithin and cholesterol was successfully developed, suggesting that treatment with the nanoparticles might reverse some AD symptoms. Therefore, these nanoparticles might be used as promising new candidates for the delivery of HAS to treat AD. Keywords: hydroxy-α-sanshool, intranasal liposome, Alzheimer's disease As the ageing population increases and due to progressive nature of disease, Alzheimer's disease (AD) has become one of the most common diseases in the elderly population and is a serious threat to the lives of the elderly. 1 AD is a progressive neurodegenerative disease and its onset is insidious, long, and irreversible. A previous study suggested that the clinical symptoms of AD are divided into memory and cognitive impairments, accompanied by reduced self-care ability and abnormal mental manifestations while its aetiology and pathogenesis are still not fully understood. 2,3 Furthermore, the pathological features of AD are the presence of senile plaques and neurofibrillary tangles in the brain, while its proposed pathogenic mechanisms mainly include cholinergic dysfunction, the tau protein hyperphosphorylation hypothesis, the Aβ cascade hypothesis and the oxidative stress hypothesis. 4–6 Nevertheless, the current drug pipeline for AD in clinical trials remains dry, as cholinesterase inhibitors and glutamate receptor antagonists only ameliorate symptoms and do not cure the disease. 7 In addition, which is the most fragile and important organ in the human body, has a blood–brain barrier (BBB) composed of capillary endothelial cells that are closely apposed by tight intercellular junctions that lack fenestrations and have high transendothelial electrical resistance, thereby limiting the paracellular diffusion of solutes or drugs. 8,9 Intranasal drug delivery, a noninvasive drug administration approach, is a traditional treatment that is mainly applied to local nasal diseases. Interestingly, this traditional treatment has attracted increasing interest in recent years since it directly delivers a drug to the cerebrospinal fluid which can not only maintains the integrity of the drug but also achieves targeting, circumventing the BBB. 10 Therefore, nasal administration of treatments for neurodegenerative diseases has also received increasing attention. 11 For example, after nasal administration, drugs exert their effects by stimulating the olfactory nerve, facial nerve and the ocular and maxillary branches of the trigeminal nerve in the nasal cavity. 12 However, different results have also been reported for the time and content -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology